Ocugen的视网膜炎色素基因疗法先进,第三阶段的入学完成,预计2027年将获得数据。 Ocugen's gene therapy for retinitis pigmentosa advanced, with Phase 3 enrollment complete and data expected in 2027.

Ocugen报告了2025年第四季度的结果,按照预期,每股净损失0.6美元,因为研发支出增至1 070万美元。 Ocugen reported fourth-quarter 2025 results with a net loss of $0.06 per share, in line with expectations, as R&D spending rose to $10.7 million. 该公司推进了基因治疗管道,完成了LiMeliGhT试验第3阶段的注册,为OCU400进行试验,这是对视网膜炎色素的潜在治疗,头线数据预计将在Q1 2027中提供。 The company advanced its gene therapy pipeline, completing Phase 3 enrollment in the liMeliGhT trial for OCU400, a potential treatment for retinitis pigmentosa, with top-line data expected in Q1 2027. 早期数据显示,损伤增长和持续视觉改善减少了46%。 Early data showed a 46% reduction in lesion growth and sustained visual improvements. 计划在Q3 2026年推出一个滚动生物学许可证申请,目标是2027年实现商业化。 A rolling Biologics License Application is planned for Q3 2026, with commercialization targeted for 2027. 欧洲药品署证实美国试验数据可以支持欧盟的申请。 The European Medicines Agency confirmed U.S. trial data can support an EU application. 预计现金储备将持续到2026年4月,如果充分行使逮捕令,可能会延长到2027年。 Cash reserves are projected to last through Q4 2026, with potential extension into 2027 if warrants are fully exercised.